<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Bras Pneumol</journal-id>
      <journal-id journal-id-type="iso-abbrev">J Bras Pneumol</journal-id>
      <journal-id journal-id-type="publisher-id">jbpneu</journal-id>
      <journal-title-group>
        <journal-title>Jornal Brasileiro de Pneumologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1806-3713</issn>
      <issn pub-type="epub">1806-3756</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Pneumologia e Tisiologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26578143</article-id>
      <article-id pub-id-type="pmc">4635098</article-id>
      <article-id pub-id-type="doi">10.1590/S1806-37132015000000095</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letter To The Editor</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Bronchiectasis caused by common variable immunodeficiency</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Divino</surname>
            <given-names>Paulo Henrique do Amor</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Basilio</surname>
            <given-names>Jos&#xE9; Henrique de Carvalho</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Fabbri</surname>
            <given-names>Renato Moraes Alves</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bastos</surname>
            <given-names>Igor Pol&#xF4;nio</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Forte</surname>
            <given-names>Wilma Carvalho Neves</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>1</label>Departamento de Medicina, Irmandade da Santa Casa de Miseric&#xF3;rdia de S&#xE3;o Paulo, S&#xE3;o Paulo, Brasil</aff>
      <aff id="aff2"><label>2</label>Disciplina de Imunologia, Faculdade de Ci&#xEA;ncias M&#xE9;dicas da Santa Casa de S&#xE3;o Paulo, S&#xE3;o Paulo, Brasil</aff>
      <pub-date pub-type="epub-ppub">
        <season>Sep-Oct</season>
        <year>2015</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>Sep-Oct</season>
        <year>2015</year>
      </pub-date>
      <volume>41</volume>
      <issue>5</issue>
      <fpage>482</fpage>
      <lpage>483</lpage>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License</license-p>
        </license>
      </permissions>
      <counts>
        <fig-count count="2"/>
        <table-count count="0"/>
        <equation-count count="0"/>
        <ref-count count="10"/>
        <page-count count="2"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>TO THE EDITOR:</title>
      <p>Primary immunodeficiencies (PIDs) are characterized by impairment of one or more arms of the immune response, resulting in decreased defense, an increased number of infections, and, in certain cases, a higher incidence of autoimmune diseases and cancers.<sup>(</sup>
<xref rid="B01" ref-type="bibr">1</xref>
<sup>)</sup> Although PIDs are considered rare diseases, many of them are more common than are those currently diagnosed with the "heel prick" test. The manifestations of PIDs are heterogeneous and are usually caused by genetic defects of the immune system and its development.</p>
      <p>Common variable immunodeficiency (CVI) is the most prevalent of the severe PIDs. A diagnosis of CVI is based on reduced levels of IgG, IgA, and (in some cases) IgM, together with reduced levels of specific antibodies, after other causes of hypogammaglobulinemia have been excluded.<sup>(</sup>
<xref rid="B02" ref-type="bibr">2</xref>
<sup>)</sup> The incidence of CVI is similar in both genders, with either sporadic or familial distribution. Although it can manifest at any time in life, it is especially common in adolescence and young adulthood. The most striking characteristics of this disease include hypogammaglobulinemia associated with frequent infections, especially with encapsulated bacteria, as well as a poor response to immunization protocols.<sup>(</sup>
<xref rid="B03" ref-type="bibr">3</xref>
<sup>)</sup>
</p>
      <p>A 27-year-old Black female, who worked as a maid, was admitted to the ER of a tertiary hospital with a 7-day history of productive cough, fever, and dyspnea. The patient reported a history of asthma, recurrent pneumonia, and some episodes of furunculosis. In addition, she reported that, one month prior, she had been hospitalized for five days because of pneumonia and that the frequency of such infections had increased in the last five years.</p>
      <p>The initial examination revealed fever, an SpO<sub>2</sub> of 84% on room air (digital pulse oximetry), a heart rate of 120 bpm, and an arterial pressure of 90/60 mmHg. A chest X-ray of the chest showed right pleural effusion as well as pneumonic infiltrates in the middle third and lower lobe of the left lung (<xref ref-type="fig" rid="f01">Figure 1</xref>). The patient was started on antibiotic therapy to treat the pulmonary focus and underwent thoracentesis followed by chest tube drainage, on the right side, because of empyema.</p>
      <p>
<fig id="f01" orientation="portrait" position="float"><label>Figure 1.</label><caption><title>Chest X-ray showing right pleural effusion as well as pneumonic infiltrates in the middle third and lower lobe of the left lung.</title></caption><graphic xlink:href="1806-3713-jbpneu-41-05-00482-gf01"/></fig>
</p>
      <p>The patient was found to be antinuclear factor-negative. Serology for HIV, HTLV, hepatitis A, hepatitis B, hepatitis C, Epstein-Barr virus, rubella, toxoplasmosis, and cytomegalovirus was negative, as was the venereal disease research laboratory test (for syphilis). In addition, sputum smear microscopy and sputum cultures were negative for tuberculosis and fungi. No bacteria were isolated from blood or pleural fluid culture. The results of thyroid function testing, anti-thyroglobulin testing, and anti-thyroid peroxidase testing were normal, ruling out the possibility of autoimmune thyroiditis. Quantification of serum immunoglobulins revealed a persistent decrease in IgA, IgM, and IgG. Serology was negative for antibody to hepatitis B surface antigen (anti-HBs), although the patient had received three doses of the hepatitis B vaccine. Additional immunological assessment, which included determination of total complement activity (CH50), photoreduction of nitroblue tetrazolium, and measurement of phagocytosis by neutrophils and mononuclear phagocytes, yielded normal results.</p>
      <p>On the basis of the clinical picture, findings from history taking, and laboratory test results, a diagnosis of CVI was made and the patient was started on human immunoglobulin replacement therapy (600 mg/kg), which resulted in rapid clinical and radiological improvement. Two months after admission, the patient was discharged to follow-up in the pulmonology and allergy/immunodeficiency outpatient clinics for continuation of her immunoglobulin replacement therapy (monthly administration).</p>
      <p>Recurrent pneumonia can result in bronchiectasis and forms part of the core clinical picture of CVI. Among PIDs, CVI is the second most common, although it is believed to be underdiagnosed. Its incidence is reported as 1:10,000 among individuals of European descent, being rare among Asians, with a reported incidence of 1:2,000,000 individuals in Japan.<sup>(</sup>
<xref rid="B04" ref-type="bibr">4</xref>
<sup>)</sup> To date, there have been no studies investigating its incidence in the Black population.</p>
      <p>Encapsulated bacteria, such as <italic>Streptococcus pneumoniae </italic>and<italic> Haemophilus influenzae</italic>, are combated by IgG2 subclass antibodies to polysaccharide antigens. In the absence of such immunoglobulins, as in cases of CVI, patients experience sinopulmonary infections, especially pneumonia, bronchitis, sinusitis, and otitis.<sup>(</sup>
<xref rid="B01" ref-type="bibr">1</xref>
<sup>,</sup>
<xref rid="B02" ref-type="bibr">2</xref>
<sup>)</sup> Infections with atypical bacteria, such as some species of the genus <italic>Mycoplasma</italic>, have also been reported<italic>.</italic>
<sup>(</sup>
<xref rid="B05" ref-type="bibr">5</xref>
<sup>)</sup> Often, patients experience tonsillitis, otitis, and giardiasis in childhood, all of which are facilitated by IgA deficiency, and, in adolescence or young adulthood, develop recurrent pneumonia, which is characteristic of IgG deficiency, suggesting that CVI is the result of progression of IgA deficiency.<sup>(</sup>
<xref rid="B06" ref-type="bibr">6</xref>
<sup>)</sup>
</p>
      <p>The patient in question had been immunized against hepatitis B, as recommended, having received all three doses of the vaccine. Nevertheless, she tested negative for anti-HBs, i.e., she had deficient production of specific protein antibodies, which also occurs in CVI.<sup>(</sup>
<xref rid="B02" ref-type="bibr">2</xref>
<sup>)</sup> In this PID, there can be deficient production of other specific antibodies, especially those to polysaccharide antigens, and the pneumococcal vaccination status of the patient must therefore be taken into account.</p>
      <p>Patients with CVI have normal or slightly reduced B lymphocyte counts. However, because of problems intrinsic to B lymphocytes, they can lack the ability to differentiate into antibody-producing plasma cells, might not function properly as antigen-presenting cells to T helper lymphocytes, or might not receive sufficient assistance from T helper lymphocytes, all of which can impair the response to immunizations and infections. <sup>(</sup>
<xref rid="B03" ref-type="bibr">3</xref>
<sup>-</sup>
<xref rid="B07" ref-type="bibr">7</xref>
<sup>)</sup> Such problems are probably due to disturbances in the expression of surface molecules on B lymphocytes or T helper lymphocytes, intracellular enzyme activity disturbances, or increased apoptosis.<sup>(</sup>
<xref rid="B08" ref-type="bibr">8</xref>
<sup>)</sup>
</p>
      <p>The prevalence of chronic pulmonary complications at CVI diagnosis is high (27.0-34.2%).<sup>(</sup>
<xref rid="B09" ref-type="bibr">9</xref>
<sup>)</sup> The most common such complication is bronchiectasis. Extensive pneumonia and the chronicity of infectious pulmonary episodes are responsible for the poor prognosis in CVI patients.<sup>(</sup>
<xref rid="B10" ref-type="bibr">10</xref>
<sup>)</sup> Bronchiectasis can accompany diseases and conditions other than CVI, including tuberculosis, aspergillosis, cystic fibrosis,alpha-1 antitrypsin deficiency, AIDS, cancer, systemic lupus erythematosus, and rheumatoid arthritis. Therefore, it is necessary to make the differential diagnosis, whether it is based on findings from history taking or on ancillary test results.</p>
      <p>The treatment for patients with CVI includes administering human immunoglobulin replacement therapy and combating infections. Immunoglobulin preparations contain neutralizing antibodies against a wide variety of bacteria and viruses, reflecting the immunological memory of the donors, and should be administered every three or four weeks.</p>
      <p>We believe that CVI should be borne in mind by health professionals who treat patients with recurrent pneumonia. Typically manifesting in adulthood, CVI is a PID that must be diagnosed early so that prompt treatment can be instituted, thereby lowering morbidity, improving quality of life, and, in many cases, making survival possible for these patients.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="B01">
        <label>1</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Forte</surname>
              <given-names>WC</given-names>
            </name>
          </person-group>
          <source>Imunologia do B&#xE1;sico ao Aplicado</source>
          <publisher-loc>S&#xE3;o Paulo</publisher-loc>
          <publisher-name>Atheneu</publisher-name>
          <year>2015</year>
          <fpage>339</fpage>
          <lpage>339</lpage>
        </element-citation>
      </ref>
      <ref id="B02">
        <label>2</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <collab>European Society of Immunodeficiencies--Esid</collab>
          </person-group>
          <publisher-loc>Geneva</publisher-loc>
          <publisher-name>Esid</publisher-name>
          <source>[homepage on the Internet]</source>
          <year>2015</year>
          <ext-link ext-link-type="uri" xlink:href="http://www.esid.org">http://www.esid.org</ext-link>
        </element-citation>
      </ref>
      <ref id="B03">
        <label>3</label>
        <element-citation publication-type="journal">
          <article-title>Primary immunodeficiency diseases: report of a WHO scientific group</article-title>
          <source>Clin Exp Immunol</source>
          <year>1997</year>
          <volume>109 Suppl 1</volume>
          <fpage>1</fpage>
          <lpage>28</lpage>
        </element-citation>
      </ref>
      <ref id="B04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kokron</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Errante</surname>
              <given-names>PR</given-names>
            </name>
            <name>
              <surname>Barros</surname>
              <given-names>MT</given-names>
            </name>
            <name>
              <surname>Baracho</surname>
              <given-names>GV</given-names>
            </name>
            <name>
              <surname>Camargo</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Kalil</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Clinical and laboratory aspects of common variable immunodeficiency</article-title>
          <source>An Acad Bras Cienc</source>
          <year>2004</year>
          <volume>76</volume>
          <issue>4</issue>
          <fpage>707</fpage>
          <lpage>726</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1590/S0001-37652004000400007">http://dx.doi.org/10.1590/S0001-37652004000400007</ext-link>
          <pub-id pub-id-type="pmid">15558152</pub-id>
        </element-citation>
      </ref>
      <ref id="B05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cunningham-Rundles</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Bodian</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Common variable immunodeficiency: clinical and immunological features of 248 patients</article-title>
          <source>Clin Immunol</source>
          <year>1999</year>
          <volume>92</volume>
          <issue>1</issue>
          <fpage>34</fpage>
          <lpage>48</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1006/clim.1999.4725">http://dx.doi.org/10.1006/clim.1999.4725</ext-link>
          <pub-id pub-id-type="pmid">10413651</pub-id>
        </element-citation>
      </ref>
      <ref id="B06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carvalho Neves Forte</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Ferreira De Carvalho</surname>
              <given-names>F</given-names>
              <suffix>J&#xFA;nior</suffix>
            </name>
            <name>
              <surname>Damaceno</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Vidal Perez</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Gonzales Lopes</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Mastroti</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
          <article-title>Evolution of IgA deficiency to IgG subclass deficiency and common variable immunodeficiency</article-title>
          <source>Alergol Immunopathol (Madr)</source>
          <year>2000</year>
          <volume>28</volume>
          <issue>1</issue>
          <fpage>18</fpage>
          <lpage>20</lpage>
        </element-citation>
      </ref>
      <ref id="B07">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Conley</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Notarangelo</surname>
              <given-names>LD</given-names>
            </name>
            <name>
              <surname>Etzoni</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Diagnostic criteria for primary immunodeficiencies Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies)</article-title>
          <source>Clin Immunol</source>
          <year>1999</year>
          <volume>93</volume>
          <issue>3</issue>
          <fpage>190</fpage>
          <lpage>197</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1006/clim.1999.4799">http://dx.doi.org/10.1006/clim.1999.4799</ext-link>
          <pub-id pub-id-type="pmid">10600329</pub-id>
        </element-citation>
      </ref>
      <ref id="B08">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Errante</surname>
              <given-names>PR</given-names>
            </name>
            <name>
              <surname>Condino-Neto</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Imunodefici&#xEA;ncia comum vari&#xE1;vel: revis&#xE3;o da literatura</article-title>
          <source>Rev Bras Alerg Imunopatol</source>
          <year>2008</year>
          <volume>31</volume>
          <issue>1</issue>
          <fpage>10</fpage>
          <lpage>18</lpage>
        </element-citation>
      </ref>
      <ref id="B09">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Roxo</surname>
              <given-names>P</given-names>
              <suffix>Junior</suffix>
            </name>
          </person-group>
          <article-title>Primary immunodeficiency diseases: relevant aspects for pulmonologists</article-title>
          <source>J Bras Pneumol</source>
          <year>2009</year>
          <volume>35</volume>
          <issue>10</issue>
          <fpage>1008</fpage>
          <lpage>1017</lpage>
          <pub-id pub-id-type="pmid">19918634</pub-id>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Costa-Carvalho</surname>
              <given-names>BT</given-names>
            </name>
            <name>
              <surname>Cocco</surname>
              <given-names>RR</given-names>
            </name>
            <name>
              <surname>Rodrigues</surname>
              <given-names>WM</given-names>
            </name>
            <name>
              <surname>Colla</surname>
              <given-names>VA</given-names>
            </name>
            <name>
              <surname>Sol&#xE9;</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Carneiro-Sampaio</surname>
              <given-names>MM</given-names>
            </name>
          </person-group>
          <article-title>Pneumonias de repeti&#xE7;&#xE3;o em paciente com defici&#xEA;ncia de anticorpos e imunoglobulinas normais</article-title>
          <source>J Pneumol</source>
          <year>2002</year>
          <volume>28</volume>
          <issue>3</issue>
          <fpage>155</fpage>
          <lpage>158</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1590/S0102-35862002000300008">http://dx.doi.org/10.1590/S0102-35862002000300008</ext-link>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article id="S01" article-type="translation" xml:lang="pt">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Carta Ao Editor</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Bronquiectasia por imunodefici&#xEA;ncia comum vari&#xE1;vel</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Divino</surname>
            <given-names>Paulo Henrique do Amor</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Basilio</surname>
            <given-names>Jos&#xE9; Henrique de Carvalho</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Fabbri</surname>
            <given-names>Renato Moraes Alves</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bastos</surname>
            <given-names>Igor Pol&#xF4;nio</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Forte</surname>
            <given-names>Wilma Carvalho Neves</given-names>
          </name>
          <xref ref-type="aff" rid="aff02">
<sup>2</sup>
</xref>
        </contrib>
      </contrib-group>
      <aff id="aff01"><label>1</label>Departamento de Medicina, Irmandade da Santa Casa de Miseric&#xF3;rdia de S&#xE3;o Paulo, S&#xE3;o Paulo (SP) Brasil.</aff>
      <aff id="aff02"><label>2</label>Disciplina de Imunologia, Faculdade de Ci&#xEA;ncias M&#xE9;dicas da Santa Casa de S&#xE3;o Paulo, S&#xE3;o Paulo (SP) Brasil.</aff>
    </front-stub>
    <body>
      <sec>
        <title>AO EDITOR:</title>
        <p>As imunodefici&#xEA;ncias prim&#xE1;rias (IDPs) s&#xE3;o caracterizadas pelo comprometimento de um ou mais setores da resposta imunol&#xF3;gica, resultando em menor defesa, aumento de infec&#xE7;&#xF5;es e, em certos casos, maior incid&#xEA;ncia de doen&#xE7;as autoimunes e neoplasias.<sup>(</sup>
<xref rid="B01" ref-type="bibr">1</xref>
<sup>)</sup> S&#xE3;o consideradas doen&#xE7;as raras, embora muitas delas sejam mais frequentes do que as atualmente diagnosticadas pelo "teste do pezinho". Suas manifesta&#xE7;&#xF5;es s&#xE3;o heterog&#xEA;neas e surgem geralmente por defeitos gen&#xE9;ticos do sistema imunol&#xF3;gico e do seu desenvolvimento.</p>
        <p>A imunodefici&#xEA;ncia comum vari&#xE1;vel (ICV) &#xE9; a mais prevalente entre as IDPs graves. &#xC9; caracterizada por diminui&#xE7;&#xE3;o de IgG e IgA e/ou IgM, assim como diminui&#xE7;&#xE3;o de anticorpos espec&#xED;ficos, depois de exclu&#xED;das outras causas de hipogamaglobulinemia. <sup>(</sup>
<xref rid="B02" ref-type="bibr">2</xref>
<sup>)</sup> A incid&#xEA;ncia de ICV &#xE9; semelhante nos dois g&#xEA;neros, com distribui&#xE7;&#xE3;o espor&#xE1;dica ou familiar, podendo se manifestar em qualquer &#xE9;poca da vida, principalmente em adolescentes e adultos jovens. As caracter&#xED;sticas mais marcantes dessa doen&#xE7;a s&#xE3;o a hipogamaglobulinemia associada a infec&#xE7;&#xF5;es frequentes, principalmente por bact&#xE9;rias encapsuladas, al&#xE9;m de resposta deficit&#xE1;ria a protocolos de imuniza&#xE7;&#xF5;es.<sup>(</sup>
<xref rid="B03" ref-type="bibr">3</xref>
<sup>)</sup>
</p>
        <p>Uma mulher, negra, 27 anos, dom&#xE9;stica, foi admitida no PS de um hospital terci&#xE1;rio com quadro de tosse produtiva, febre e dispneia h&#xE1; sete dias. Na hist&#xF3;ria cl&#xED;nica, referia asma, pneumonias de repeti&#xE7;&#xE3;o e alguns epis&#xF3;dios de furunculose ao longo da vida. Relatava interna&#xE7;&#xE3;o h&#xE1; um m&#xEA;s por pneumonia, durante cinco dias, e referia aumento da frequ&#xEA;ncia dessas infec&#xE7;&#xF5;es nos &#xFA;ltimos cinco anos.</p>
        <p>Ao exame inicial, apresentava-se febril, taquidispneica, SpO<sub>2</sub> de 84% em ar ambiente por oximetria digital, frequ&#xEA;ncia card&#xED;aca de 120 bpm e press&#xE3;o arterial de 90/60 mmHg. A imagem radiol&#xF3;gica de t&#xF3;rax mostrou derrame pleural &#xE0; direita e infiltrado pneum&#xF4;nico em ter&#xE7;o m&#xE9;dio e em lobo inferior de hemit&#xF3;rax esquerdo (<xref ref-type="fig" rid="f1">Figura 1</xref>). Foi iniciada antibioticoterapia para o foco pulmonar, assim como foram realizadas toracocentese seguida de drenagem tor&#xE1;cica direita devido a empiema.</p>
        <p>
<fig id="f1" orientation="portrait" position="float"><label>Figura 1.</label><caption><title>Radiografia de t&#xF3;rax mostrando derrame pleural &#xE0; direita e infiltrado pneum&#xF4;nico em ter&#xE7;o m&#xE9;dio e em lobo inferior de hemit&#xF3;rax esquerdo.</title></caption><graphic xlink:href="1806-3713-jbpneu-41-05-00482-gf01-pt"/></fig>
</p>
        <p>Os exames complementares mostraram-se negativos: FAN, sorologias para HIV, HTLV, hepatites A, B e C, v&#xED;rus Epstein-Barr, rub&#xE9;ola, toxoplasmose, citomegalov&#xED;rus, s&#xED;filis (VDRL), baciloscopias de escarro e culturas de escarro para fungos e tuberculose. N&#xE3;o foram isoladas bact&#xE9;rias na hemocultura e na cultura do l&#xED;quido pleural<italic>. </italic>Os exames para fun&#xE7;&#xE3;o tireoidiana, antitireoglobulina e antitireoperoxidase mostraram-se normais, afastando-se a possibilidade de tireoidite autoimune. As imunoglobulinas s&#xE9;ricas revelaram diminui&#xE7;&#xE3;o persistente de IgA, IgM e IgG. A sorologia para ant&#xED;geno de superf&#xED;cie de v&#xED;rus de hepatite B (anti-HBs) foi n&#xE3;o reagente, embora a paciente tivesse recebido tr&#xEA;s doses de vacina&#xE7;&#xE3;o. Os demais exames imunol&#xF3;gicos foram normais: dosagem do complemento total (CH50), fotorredu&#xE7;&#xE3;o do azul de nitrotetraz&#xF3;lio e ingest&#xE3;o da fagocitose por neutr&#xF3;filos e por fag&#xF3;citos mononucleares.</p>
        <p>Diante do quadro cl&#xED;nico, anamnese e exames laboratoriais, foi feito o diagn&#xF3;stico de ICV e indicada a reposi&#xE7;&#xE3;o com imunoglobulina humana (600 mg/kg), havendo r&#xE1;pida melhora cl&#xED;nica e radiol&#xF3;gica. Dois meses ap&#xF3;s a interna&#xE7;&#xE3;o, a paciente recebeu alta hospitalar, passando a ser acompanhada nos ambulat&#xF3;rios de pneumologia e de alergia e imunodefici&#xEA;ncias para continuar a reposi&#xE7;&#xE3;o de imunoglobulina mensalmente.</p>
        <p>Pneumonias de repeti&#xE7;&#xE3;o podem ter como consequ&#xEA;ncia bronquiectasias e fazem parte do quadro cl&#xED;nico principal da ICV. Entre as IDPs, a ICV &#xE9; a segunda mais comum, apesar de se acreditar que seu diagn&#xF3;stico seja subestimado. Sua incid&#xEA;ncia &#xE9; descrita em 1:10.000 caucasianos, sendo rara em japoneses (1:2.000.000). <sup>(</sup>
<xref rid="B04" ref-type="bibr">4</xref>
<sup>)</sup> At&#xE9; o momento, n&#xE3;o h&#xE1; estudos sobre sua incid&#xEA;ncia na popula&#xE7;&#xE3;o negra.</p>
        <p>As bact&#xE9;rias encapsuladas, como <italic>Streptococcus pneumoniae </italic>e<italic> Haemophilus influenzae</italic>, s&#xE3;o combatidas por anticorpos a ant&#xED;genos polissacar&#xED;deos, contidos na subclasse IgG2. Na falta de tais imunoglobulinas, como na ICV, o paciente apresenta infec&#xE7;&#xF5;es sinopulmonares, em especial pneumonias, bronquites, sinusites e otites. <sup>(</sup>
<xref rid="B01" ref-type="bibr">1</xref>
<sup>,</sup>
<xref rid="B02" ref-type="bibr">2</xref>
<sup>)</sup> S&#xE3;o descritas ainda infec&#xE7;&#xF5;es por bact&#xE9;rias at&#xED;picas, como algumas esp&#xE9;cies do g&#xEA;nero <italic>Mycoplasma.</italic>
<sup>(</sup>
<xref rid="B05" ref-type="bibr">5</xref>
<sup>)</sup> Muitas vezes os pacientes apresentam quadros de amigdalites, otites e giard&#xED;ase na inf&#xE2;ncia, facilitados pela defici&#xEA;ncia de IgA e, quando adolescentes ou adultos jovens, passam a ter pneumonias de repeti&#xE7;&#xE3;o, caracter&#xED;sticas da defici&#xEA;ncia de IgG, sugerindo que a ICV possa ser uma evolu&#xE7;&#xE3;o da defici&#xEA;ncia de IgA.<sup>(</sup>
<xref rid="B06" ref-type="bibr">6</xref>
<sup>)</sup>
</p>
        <p>A paciente em quest&#xE3;o havia sido imunizada contra hepatite B, conforme preconizado, recebendo as tr&#xEA;s doses da vacina. Apesar disso, apresentava anti-HBs n&#xE3;o reagente, ou seja, apresentava defici&#xEA;ncia da produ&#xE7;&#xE3;o de anticorpos proteicos espec&#xED;ficos, o que tamb&#xE9;m ocorre na ICV.<sup>(</sup>
<xref rid="B02" ref-type="bibr">2</xref>
<sup>)</sup> Nessa IDP, pode haver defici&#xEA;ncia de outros anticorpos espec&#xED;ficos, em especial a ant&#xED;genos polissacar&#xED;deos, tendo-se que levar em considera&#xE7;&#xE3;o a vacina&#xE7;&#xE3;o antipneumoc&#xF3;cica do paciente para essa avalia&#xE7;&#xE3;o.</p>
        <p>Pacientes com ICV apresentam n&#xFA;mero normal ou discretamente diminu&#xED;do de linf&#xF3;citos B. Entretanto, esses linf&#xF3;citos n&#xE3;o t&#xEA;m a capacidade para se diferenciar em plasm&#xF3;citos bons produtores de anticorpos, n&#xE3;o atuam perfeitamente como c&#xE9;lulas apresentadoras de ant&#xED;genos para linf&#xF3;citos T auxiliares ou n&#xE3;o recebem a coopera&#xE7;&#xE3;o suficiente de linf&#xF3;citos T auxiliares, devido a problemas intr&#xED;nsecos dessas c&#xE9;lulas: tais fatos prejudicam a resposta a imuniza&#xE7;&#xF5;es e infec&#xE7;&#xF5;es. <sup>(</sup>
<xref rid="B03" ref-type="bibr">3</xref>
<sup>-</sup>
<xref rid="B07" ref-type="bibr">7</xref>
<sup>)</sup> Essas altera&#xE7;&#xF5;es provavelmente s&#xE3;o devidas a dist&#xFA;rbios da express&#xE3;o de mol&#xE9;culas de superf&#xED;cie em linf&#xF3;citos B e/ou T auxiliares, da atividade enzim&#xE1;tica intracelular ou do aumento da apoptose.<sup>(</sup>
<xref rid="B08" ref-type="bibr">8</xref>
<sup>)</sup>
</p>
        <p>Complica&#xE7;&#xF5;es pulmonares cr&#xF4;nicas t&#xEA;m alta preval&#xEA;ncia (27,0-34,2%) no momento em que se diagnostica a ICV.<sup>(</sup>
<xref rid="B09" ref-type="bibr">9</xref>
<sup>)</sup> As bronquiectasias s&#xE3;o as complica&#xE7;&#xF5;es cl&#xED;nicas mais frequentes dessa doen&#xE7;a. Pneumonias extensas e a cronicidade de eventos infecciosos pulmonares s&#xE3;o respons&#xE1;veis por determinar um pior progn&#xF3;stico para o paciente.<sup>(</sup>
<xref rid="B10" ref-type="bibr">10</xref>
<sup>)</sup> Al&#xE9;m da ICV, outras doen&#xE7;as podem cursar com bronquiectasias: tuberculose, aspergilose, fibrose c&#xED;stica, defici&#xEA;ncia de alfa-1 antitripsina, AIDS, neoplasias, l&#xFA;pus eritematoso sist&#xEA;mico, artrite reumatoide, dentre outras, tornando-se necess&#xE1;rio o diagn&#xF3;stico de exclus&#xE3;o, seja por anamnese, seja por exames complementares.</p>
        <p>O tratamento para pacientes com ICV inclui a reposi&#xE7;&#xE3;o de imunoglobulina humana e combate &#xE0;s infec&#xE7;&#xF5;es. As prepara&#xE7;&#xF5;es de imunoglobulina cont&#xEA;m anticorpos neutralizantes contra uma grande variedade de bact&#xE9;rias e v&#xED;rus, refletindo a mem&#xF3;ria imunol&#xF3;gica dos doadores, e devem ser administradas a cada tr&#xEA;s ou quatro semanas.</p>
        <p>Acreditamos que a ICV deva ser lembrada entre os profissionais de sa&#xFA;de que cuidam de pacientes com pneumonias de repeti&#xE7;&#xE3;o. &#xC9; uma IDP que geralmente se manifesta na vida adulta e que deve ser diagnosticada precocemente para uma r&#xE1;pida institui&#xE7;&#xE3;o terap&#xEA;utica, gerando menor morbidade, melhorando a qualidade de vida e, muitas vezes, possibilitando a sobrevida desses pacientes.</p>
      </sec>
    </body>
  </sub-article>
</article>
</pmc-articleset>
